

## Lecture Series *CCC-N Cancer Club*

Prof. Dr. med. Günter Schneider (UMG), PD Dr. Matthias Wirth (UMG),  
and PD Dr. Anna Saborowski (MHH)

(previous co-organizers: Gudrun Göhring (MHH), Anke Bergmann (MHH))

### List of previous talks in the series:

1. 07.02.2022  
**Dr. med. Raphael Koch**, Department of Hematology and Medical Oncology (UMG)  
*Exploring functional vulnerabilities in T-cell lymphoma and beyond*
2. 07.03.2022  
**Prof. Dr. med. Klaus Pantel**, Institute of Tumor Biology (UKE Hamburg)  
*Liquid Biopsy: From Discovery to Clinical Implementation*
3. 25.04.2022  
**PD Dr. med. Thomas Wirth**, Department of Gastroenterology, Hepatology and Endocrinology (MHH)  
*Immunotherapy of GI Cancers. From Checkpoint Inhibition to Personalized Vaccines*
4. 16.05.2022  
**PD Dr. Dr. Lena Conradi**, Department of General, Visceral and Pediatric Surgery (UMG)  
*Vessel Co-option versus Angiogenesis in Colorectal Cancer Liver Metastases*
5. 20.06.2022  
**Dr. Sonja Woermann**, Ahmed Center for Pancreatic Cancer Research, The University of Texas MD Anderson Cancer Center, US  
*The Role of APOBEC3A in Pancreatic Cancer*
6. 05.09.2022  
**Prof. Dr. med. Diana Steinmann**, Clinic for Radiotherapy and Special Oncology (MHH)  
*Complementary Medicine in Oncology - What Else Can Patients Do?*
7. 10.10.2022  
**Dr. Arnab Nayak**, Institute for Molecular and Cell Physiology (MHH)  
*Cachexia and the SUMO pathway – a new paradigm of muscle wasting disorders*
8. 24.10.2022  
**Dr. Benedikt Westphalen**, CCC Munich (LMU)  
*Access to innovative care - scaling precision oncology*
9. 07.11.2022  
**Dr. Asha Balakrishnan**, Department of Gastroenterology, Hepatology and Endocrinology (MHH)  
*Interactions between cellular processes, metabolic pathways, and miRNAs in HCC*
10. 05.12.2022  
**Dr. Shiv Singh**, Department of Gastroenterology, Gastrointestinal Oncology, and Endocrinology (UMG)  
*Cell-extrinsic and –intrinsic mechanisms in pancreatic cancer heterogeneity and therapy response*
11. 12.12.2022  
**Prof. Dr. med. Jens Siveke**, WTZ Essen  
*Translational approaches in pancreatic cancer*

12. 09.01.2023  
**Dr. Benedikt Nilges**, ESBC Leuven  
*Studying tumor heterogeneity and microenvironments with single cell spatial transcriptomics*
13. 06.02.2023  
**Dr. Sara Haag** (TRAIN Niedersachsen) & **PD Dr. Sara Nußbeck** (UMG)  
*Lower Saxony Unified Biobank – An Infrastructure to Support Translational Research*
14. 20.02.2023  
**Alexander Berg & Dr. Liat Hayardeny-Brueck** (both UMG Knowledge and Technology Transfer)  
*From Bench to Bedside – How the UMG Accelerates Drug Development*
15. 01.03.2023  
**Prof. Dr. Maximilian Reichert**, TU München  
*Functionalizing patient-derived organoids to model intra-tumoral heterogeneity in pancreatic cancer*
16. 17.04.2023  
**Prof. Dr. Marc Schmidt-Supprian**, LMU München  
*Balancing B-Cell Responses between Protective Immunity, Autoimmunity and Lymphomagenesis*
17. 15.05.2023  
**Prof. Dr. Ulrich Keller**, Charité Berlin  
*The activated MYC-SUMO axis in cancer: mechanisms and targeting*
18. 26.06.2023  
**Prof. Dr. Alexander Kleger**, Ulm  
*Epithelial genotypes determine niche reprogramming during pancreatic carcinogenesis*
19. 04.09.2023  
**Dr. Christian Braun**, Dr. von Hauner Children's Hospital, University Hospital, LMU Munich  
*Targeting imbalanced transcription programs in cancer*
20. 08.11.2023  
**Alan Coy**, Roche Pharma  
*Digitalization in Oncology*
21. 04.12.2023  
**Dr. Siegfried Hauch**, Qiagen GmbH  
*Matched Analysis of Liquid Biopsy Components in ER+ Her2-Breast Cancer – Is there a Master Analyte?*
22. 18.12.2023  
**Prof. Dr. Michael Altenbuchinger**, UMG  
*High-dimensional statistical approaches for (multi-)omics and spatial transcriptomics data: applications to cancer research*
23. 15.01.2024  
**Prof. Dr. Svenja Meierjohann**, Universität Würzburg  
*Stress adaptation in melanoma: the role of NRF2*
24. 20.02.2024  
**Prof. Dr. Hana Algül**, Technische Universität München  
*Pancreatic Carcinoma - What's Standard, What's Next?*
25. 04.03.2024  
**Prof. Dr. Uta-Maria Bauer**, Philipps Universität Marburg  
*PRMTs - important players in human malignancies*

26. 11.03.2024  
**Prof. Dr. Martin-Leo Hansmann**, Goethe Universität Frankfurt  
*Strategic lymph node diagnostics in 3D and movement-4D*
27. 08.04.2024  
**Prof. Dr. Elias Arnér**, Karolinska Institutet Stockholm  
*Small molecule inhibitors and chemical degraders (PROTACs) of oncogenic targets*
28. 29.04.2024  
**Prof. Dr Christian Reinhardt**, West German Cancer Center Essen  
*Mouse models of aggressive lymphoma as preclinical avatars to dissect biology and for the development of therapeutic strategies*
29. 05.08.2024  
**Prof. Dr. Wolfgang Sippl**, Martin-Luther-Universität Halle-Wittenberg  
*Small molecule inhibitors and chemical degraders (PROTACs) of oncogenic targets*
30. 02.09.2024  
**Prof. Dr. Florian Heidel**, Medizinische Hochschule Hannover  
*Effectors of malignant JAK-signaling*
31. 11.11.2024  
**Prof. Dr. Elmar Wolf**, Christian-Albrechts-Universität zu Kiel  
*Targeting the oncogenic function of MYC in PDAC*
32. 02.12.2024  
**Prof. Dr. Martin Sos**, Ludwig-Maximilians-Universität München  
*Exploiting molecular dependencies in lung cancer*
33. 15.01.2025  
**Dr. Dan Lu**, Harvard Medical School  
*Dynamic combinatorial p53 post-translational modifications regulate cell fate*
34. 10.02.2025  
**Prof. Dr. Gunnar Schotta**, Ludwig Maximilians Universität München  
*Silent Invaders: Unraveling the Regulation of Endogenous Retroviruses*
35. 10.03.2025  
**Prof. Dr. Stefan Hüttelmaier**, Martin-Luther-Universität Halle-Wittenberg  
*Targeting RNS Binding Proteins (RBPs) and microRNAs in Cancer Therapy*
36. 28.04.2025  
**Prof. Dr. Joanna Kalucka**, Aarhus University  
*Crosstalk Between Metabolic and Immune Pathways in Regulating Vascular Biology*
37. 05.05.2025  
**Prof. Dr. Daniel Krappmann**, LMU München  
*MALT1 paracaspase - a double-edged sword in cancer therapy*
38. 02.06.2025  
**Prof. Dr. Mathias Heikenwälder**, DKFZ Heidelberg  
*Immune microenvironment in liver cancer - the importance of metabolic alterations in health and in disease: Consequences for therapy*
39. 30.06.2025  
**Prof. Dr. Thomas Brabletz**, Universität Erlangen  
*EMT AND CELL PLASTICITY IN CANCER - DRIVING FORCE AND THERAPEUTIC TARGET*
40. 25.08.2025  
**Prof. Dr. Roland Schwarz**, Universität Köln & ICCB  
*Clonal evolution in chromosomally unstable tumours*

41. 15.09.2025  
**Dr. Markus Schick**, Astra Zeneca  
*From data to decision: AI-based computational pathology to guide ADC use in Oncology*
42. 29.09.2025  
**Prof. Dr. Jacob Piehler**, Universität Osnabrück  
*Structural and functional plasticity of cytokine receptor signaling complexes*
43. 06.10.2025  
**Prof. Dr. Ana Martin-Villalba**, DKFZ Heidelberg  
*The Perils and Promise of Polyploid Cells in the Pancreas. Implications for Tissue Remodeling, Genomic Instability, and Disease Progression*
44. 20.10.2025  
**Prof. Dr. Tilmann Brummer**, Universität Freiburg  
*Towards more effective therapies for BRAF driven cancers – from molecular mechanisms to molecular tumour boards (and back)*
45. 17.11.2025  
**Prof. Dr. Jürgen Ruland**, TU München  
*Immune Receptor Signals in T-cell Lymphoma*
46. 24.11.2025  
**Prof. Dr. Dominik Wolf**, Medizinische Universität Innsbruck  
*Myeloid inflammation - a cancer hallmark*
47. 01.12.2025  
**Dr. Michael Lidschreiber**, Max Planck Institute for Interdisciplinary Sciences  
*Transcription of the genome: molecular mechanisms and cellular regulation*
48. 15.12.2025  
**Dr. Marieke Oudelaar**, Max Planck Institute for Interdisciplinary Sciences  
*Mechanisms that drive 3D genome folding and their function in gene regulation*
49. 04.02.2026  
**Dr. Florian Perner**, Medizinische Hochschule Hannover  
*Menin inhibition in acute myeloid leukemia: resistance and persistence limiting long-term responses*